<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444259</url>
  </required_header>
  <id_info>
    <org_study_id>T273/2015</org_study_id>
    <nct_id>NCT03444259</nct_id>
  </id_info>
  <brief_title>Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients</brief_title>
  <acronym>CAREBANK</acronym>
  <official_title>Cardiovascular Research Consortium - a Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of CAREBANK study is to establish definitive relationships with human cardiac
      samples and clinical phenotypes in patients undergoing cardiac procedures. Specifically, the
      investigators aim at comparing atrial phenotypes from atrial fibrillation patients and
      controls. The work consists of three broad categories: A) role of atrial cardiomyopathy in
      atrial fibrillation; B) genetic defects predisposing to atrial fibrillation; and C) the role
      of inflammation in atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to A) compare atrial cardiomyopathy findings from the tissue samples to
      clinical phenotype and adverse events B) study the association of genetic defects
      predisposing to atrial fibrillation with atrial cardiomyopathy findings in the tissue samples
      C) assess the role of inflammation in atrial fibrillation by comparing circulating cytokine
      profiles, purinergic signaling and atrial cardiomyopathy findings in tissue samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>postoperatively until 5 years follow-up</time_frame>
    <description>Occurrence of atrial fibrillation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>postoperatively until 5 years follow-up</time_frame>
    <description>Occurrence of stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack</measure>
    <time_frame>postoperatively until 5 years follow-up</time_frame>
    <description>Occurrence of Transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>postoperatively until 5 years follow-up</time_frame>
    <description>Occurrence of Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>postoperatively until 5 years follow-up</time_frame>
    <description>Occurrence of Target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>postoperatively until 5 years follow-up</time_frame>
    <description>All-cause Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-pericardiotomy syndrome</measure>
    <time_frame>postoperatively until 1 years follow-up</time_frame>
    <description>Occurrence of Post-pericardiotomy syndrome</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Disease</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Cardiac Arrythmias</condition>
  <condition>Cardiac Tumor</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <description>Patients with atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coronary bypass</arm_group_label>
    <description>Patients undergoing coronary bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic valve replacement</arm_group_label>
    <description>Patients undergoing aortic valve replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitral valve repair</arm_group_label>
    <description>Patients undergoing mitral valve repair</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other</arm_group_label>
    <description>Patients undergoing cardiac surgery for indication other than above</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac surgery</intervention_name>
    <description>Open heart surgery</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>Coronary bypass</arm_group_label>
    <arm_group_label>Aortic valve replacement</arm_group_label>
    <arm_group_label>Mitral valve repair</arm_group_label>
    <arm_group_label>Other</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Atrial appendage, valves, ascending aorta, pericardium
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients undergoing open-heart cardiac surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any open-heart cardiac surgery

          -  Written informed consent

          -  All-comers design

        Exclusion Criteria:

          -  No informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Tuomas O Kiviniemi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jarmo Gunn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tuija Vasankari, RN</last_name>
    <phone>+35823130900</phone>
    <email>tuija.vasankari@tyks.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuomas Kiviniemi, MD, PhD</last_name>
      <phone>+35823130787</phone>
      <email>tuoski@utu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tuija Vasankari, RN</last_name>
      <phone>+35823130900</phone>
      <email>tuija.vasankari@tyks.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Jarmo Gunn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maija Hollmen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turku</investigator_affiliation>
    <investigator_full_name>Tuomas Kiviniemi</investigator_full_name>
    <investigator_title>Cardiologist, MD, PhD, FESC</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Aortic stenosis</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Atrial appendage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Heart Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

